Literature DB >> 23079694

MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma.

Edmund A Mroz1, James W Rocco.   

Abstract

OBJECTIVES: Differences among cancer cells within a tumor are important in tumorigenesis and treatment resistance, yet no measure of intratumor heterogeneity is suitable for routine application. We developed a quantitative measure of intratumor genetic heterogeneity, based on differences among mutated loci in the mutant-allele fractions determined by next-generation sequencing (NGS) of tumor DNA. We then evaluated the application of this measure to head and neck squamous cell carcinoma (HNSCC).
MATERIALS AND METHODS: We analyzed published electronically available NGS results for 74 HNSCC. For each tumor we calculated mutant-allele tumor heterogeneity (MATH) as the ratio of the width to the center of its distribution of mutant-allele fractions among tumor-specific mutated loci.
RESULTS: Intratumor heterogeneity assessed by MATH was higher in three poor-outcome classes of HNSCC: tumors with disruptive mutations in the TP53 gene (versus wild-type TP53 or non-disruptive mutations), tumors negative versus positive for human papillomavirus (even when restricted to tumors having wild-type TP53), and HPV-negative tumors from smokers with more pack-years of cigarette exposure (with TP53 status taken into account).
CONCLUSION: The relation of this type of intratumor heterogeneity to HNSCC outcome classes supports its further evaluation as a prognostic biomarker. As NGS of tumor DNA becomes widespread in clinical research and practice, MATH should provide a simple, quantitative, and clinically practical biomarker to help evaluate relations of intratumor genetic heterogeneity to outcome in any type of cancer.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23079694      PMCID: PMC3570658          DOI: 10.1016/j.oraloncology.2012.09.007

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  20 in total

Review 1.  HPV-associated head and neck cancer: a virus-related cancer epidemic.

Authors:  Shanthi Marur; Gypsyamber D'Souza; William H Westra; Arlene A Forastiere
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

2.  Human papillomavirus and survival of patients with oropharyngeal cancer.

Authors:  K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison
Journal:  N Engl J Med       Date:  2010-06-07       Impact factor: 91.245

3.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States.

Authors:  Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

4.  The mutational landscape of head and neck squamous cell carcinoma.

Authors:  Nicolas Stransky; Ann Marie Egloff; Aaron D Tward; Aleksandar D Kostic; Kristian Cibulskis; Andrey Sivachenko; Gregory V Kryukov; Michael S Lawrence; Carrie Sougnez; Aaron McKenna; Erica Shefler; Alex H Ramos; Petar Stojanov; Scott L Carter; Douglas Voet; Maria L Cortés; Daniel Auclair; Michael F Berger; Gordon Saksena; Candace Guiducci; Robert C Onofrio; Melissa Parkin; Marjorie Romkes; Joel L Weissfeld; Raja R Seethala; Lin Wang; Claudia Rangel-Escareño; Juan Carlos Fernandez-Lopez; Alfredo Hidalgo-Miranda; Jorge Melendez-Zajgla; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub; Levi A Garraway; Jennifer R Grandis
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

5.  TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.

Authors:  Heath D Skinner; Vlad C Sandulache; Thomas J Ow; Raymond E Meyn; John S Yordy; Beth M Beadle; Alison L Fitzgerald; Uma Giri; K Kian Ang; Jeffrey N Myers
Journal:  Clin Cancer Res       Date:  2011-11-16       Impact factor: 12.531

6.  Tumour evolution inferred by single-cell sequencing.

Authors:  Nicholas Navin; Jude Kendall; Jennifer Troge; Peter Andrews; Linda Rodgers; Jeanne McIndoo; Kerry Cook; Asya Stepansky; Dan Levy; Diane Esposito; Lakshmi Muthuswamy; Alex Krasnitz; W Richard McCombie; James Hicks; Michael Wigler
Journal:  Nature       Date:  2011-03-13       Impact factor: 49.962

Review 7.  Induction of genetic instability by gain-of-function p53 cancer mutants.

Authors:  Y Xu
Journal:  Oncogene       Date:  2008-01-28       Impact factor: 9.867

8.  Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone.

Authors:  L Jovanovic; B Delahunt; B McIver; N L Eberhardt; S K G Grebe
Journal:  J Pathol       Date:  2008-06       Impact factor: 7.996

9.  Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype.

Authors:  So Yeon Park; Mithat Gönen; Hee Jung Kim; Franziska Michor; Kornelia Polyak
Journal:  J Clin Invest       Date:  2010-01-25       Impact factor: 14.808

10.  Distant metastasis occurs late during the genetic evolution of pancreatic cancer.

Authors:  Shinichi Yachida; Siân Jones; Ivana Bozic; Tibor Antal; Rebecca Leary; Baojin Fu; Mihoko Kamiyama; Ralph H Hruban; James R Eshleman; Martin A Nowak; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Christine A Iacobuzio-Donahue
Journal:  Nature       Date:  2010-10-28       Impact factor: 49.962

View more
  141 in total

1.  An oral cavity squamous cell carcinoma quantitative histomorphometric-based image classifier of nuclear morphology can risk stratify patients for disease-specific survival.

Authors:  Cheng Lu; James S Lewis; William D Dupont; W Dale Plummer; Andrew Janowczyk; Anant Madabhushi
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients.

Authors:  Kerry-Ann McDonald; Tsutomu Kawaguchi; Qianya Qi; Xuan Peng; Mariko Asaoka; Jessica Young; Mateusz Opyrchal; Li Yan; Santosh Patnaik; Eigo Otsuji; Kazuaki Takabe
Journal:  Ann Surg Oncol       Date:  2019-04-08       Impact factor: 5.344

3.  Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.

Authors:  Alissa Greenbaum; David R Martin; Thèrése Bocklage; Ji-Hyun Lee; Scott A Ness; Ashwani Rajput
Journal:  Clin Colorectal Cancer       Date:  2019-02-13       Impact factor: 4.481

Review 4.  Big Bang Tumor Growth and Clonal Evolution.

Authors:  Ruping Sun; Zheng Hu; Christina Curtis
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

5.  HPV: Sex, cancer and a virus.

Authors:  Megan Scudellari
Journal:  Nature       Date:  2013-11-21       Impact factor: 49.962

6.  Tumor evolution and intratumor heterogeneity of an oropharyngeal squamous cell carcinoma revealed by whole-genome sequencing.

Authors:  Xinyi Cindy Zhang; Chang Xu; Ryan M Mitchell; Bo Zhang; Derek Zhao; Yao Li; Xin Huang; Wenhong Fan; Hongwei Wang; Luisa Angelica Lerma; Melissa P Upton; Ashley Hay; Eduardo Méndez; Lue Ping Zhao
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

7.  Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.

Authors:  David J VanderWeele; Richard Finney; Kotoe Katayama; Marc Gillard; Gladell Paner; Seiya Imoto; Rui Yamaguchi; David Wheeler; Justin Lack; Maggie Cam; Andrea Pontier; Yen Thi Minh Nguyen; Kazuhiro Maejima; Aya Sasaki-Oku; Kaoru Nakano; Hiroko Tanaka; Donald Vander Griend; Michiaki Kubo; Mark J Ratain; Satoru Miyano; Hidewaki Nakagawa
Journal:  Eur Urol Focus       Date:  2018-02-15

8.  DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway.

Authors:  Liana Adam; F Anthony San Lucas; Richard Fowler; Yao Yu; Wenhui Wu; Yulun Liu; Huamin Wang; David Menter; Michael T Tetzlaff; Joe Ensor; Ganiraju Manyam; Stefan T Arold; Chad Huff; Scott Kopetz; Paul Scheet; Michael J Overman
Journal:  Clin Cancer Res       Date:  2018-10-23       Impact factor: 12.531

Review 9.  Harnessing Tumor Evolution to Circumvent Resistance.

Authors:  Katherine L Pogrebniak; Christina Curtis
Journal:  Trends Genet       Date:  2018-06-11       Impact factor: 11.639

Review 10.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.